MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters

Frontiers in Immunology

Dolores Montenegro¹  Eugenia Puentes¹  Esteban Rodríguez¹  Adrián Lázaro-Frías²  Patricia Pérez²  Juan García-Arriaza²  David Astorgano³  Mariano Esteban³  Birgit Weynand⁴  Johan Neyts⁵  Lotte Coelmont⁵  Robbert Boudewijns⁵  Kai Dallmeier⁵  Hendrik Jan Thibaut⁶  Thomas Vercruysse⁶  Dominique Van Looveren⁶ 

[1] Biofabri, Pontevedra, Spain;Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain;Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain;KU Leuven Department of Imaging and Pathology, Translational Cell and Tissue Research, Leuven, Belgium;KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, Leuven, Belgium;KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), Leuven, Belgium;

关键词: SARS-CoV-2;    COVID-19;    MVA vaccine;    spike;    hamsters;    immunogenicity;   

DOI  :  10.3389/fimmu.2022.845969

来源: DOAJ

【 摘 要 】

To control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector expressing a human codon optimized full-length SARS-CoV-2 spike (S) protein (MVA-S). Immunization with one or two doses of MVA-S elicited high titers of S- and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against parental SARS-CoV-2 and VoC alpha, beta, gamma, delta, and omicron. After SARS-CoV-2 challenge, MVA-S-vaccinated hamsters showed a significantly strong reduction of viral RNA and infectious virus in the lungs compared to the MVA-WT control group. Moreover, a marked reduction in lung histopathology was also observed in MVA-S-vaccinated hamsters. These results favor the use of MVA-S as a potential vaccine candidate for SARS-CoV-2 in clinical trials.

【 授权许可】

Unknown